Reuters: Caveats, costs, and complexities shadow first malaria vaccine
“…Backed by billionaire philanthropist Bill Gates and developed by GlaxoSmithKline, the vaccine — called RTS,S or Mosquirix — is being assessed by regulators and global health authorities. Granting it a license and recommending it for rollout in sub-Saharan Africa, where malaria kills one child almost every minute, ought to be a no-brainer. But Mosquirix is hampered by caveats, complexities, and cost implications that threaten to make its arrival on the global health stage more of a problem than a solution, possibly not just for malaria but for vaccines in general…” (Kelland, 7/14).